Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 228
- Registration Number
- NCT00442702
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
Phase 4
Terminated
- Conditions
- Anemia
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2007-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00440063
A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Phase 2
Completed
- Conditions
- Nasopharyngeal Cancer
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 25
- Registration Number
- NCT00439426
A Study of NeoRecormon in Patients With Chronic Kidney Disease.
Phase 4
Completed
- Conditions
- Anemia
- Interventions
- Drug: epoetin beta [NeoRecormon]
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2009-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT00437723
A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis.
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT00437619
A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.
Phase 1
Terminated
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: GK Activator (2)
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT00437606
A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT00436241
A Study of Tamiflu (Oseltamivir) Treatment in Laboratory-Confirmed Influenza.
Phase 4
Terminated
- Conditions
- Influenza
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00436124
A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 39
- Registration Number
- NCT00436163
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).
Phase 4
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: peginterferon alfa-2a [Pegasys]
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 551
- Registration Number
- NCT00435825
© Copyright 2025. All Rights Reserved by MedPath